Cote d'Ivoire vs Zimbabwe: Average non-HDL cholesterol levels
Cote d'Ivoire
2.8
in 2018
Zimbabwe
2.8
in 2018
Cote d'Ivoire rank
163rd
Zimbabwe rank
163rd
Average non-HDL cholesterol levels over time
- Cote d'Ivoire
- Zimbabwe
How they compare
Cote d'Ivoire currently reports 2.8 against 2.8 in Zimbabwe, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Cote d'Ivoire ahead.
Cote d'Ivoire ranks 163rd and Zimbabwe ranks 163rd of 191 countries.
Zimbabwe has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Cote d'Ivoire | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.6 | 2.63 | 0.03 | Zimbabwe |
| 1990s | 2.7 | 2.78 | 0.08 | Zimbabwe |
| 2000s | 2.72 | 2.86 | 0.14 | Zimbabwe |
| 2010s | 2.8 | 2.88 | 0.0778 | Zimbabwe |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average non-hdl cholesterol levels, Cote d'Ivoire or Zimbabwe?
- Cote d'Ivoire, at 2.8 against 2.8 in Zimbabwe as of 2018.
- What is the difference in average non-hdl cholesterol levels between Cote d'Ivoire and Zimbabwe?
- 0, with Cote d'Ivoire ahead.
- How many years of comparable data are there for Cote d'Ivoire and Zimbabwe?
- 39 years are reported by both, from 1980 to 2018.
- How do Cote d'Ivoire and Zimbabwe rank globally for average non-hdl cholesterol levels?
- Cote d'Ivoire ranks 163rd and Zimbabwe ranks 163rd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The estimated average level of non-high-density lipoprotein (non-HDL) cholesterol, commonly known as "bad cholesterol". Healthy levels are considered to be under 4mmol/L. Elevated levels of non-HDL cholesterol are a risk factor for chronic complications, including cardiovascular disease, and premature death.